JP2006515983A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006515983A5 JP2006515983A5 JP2004527956A JP2004527956A JP2006515983A5 JP 2006515983 A5 JP2006515983 A5 JP 2006515983A5 JP 2004527956 A JP2004527956 A JP 2004527956A JP 2004527956 A JP2004527956 A JP 2004527956A JP 2006515983 A5 JP2006515983 A5 JP 2006515983A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fusion polypeptide
- residues
- sample
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 230000004927 fusion Effects 0.000 claims description 17
- 108091000080 Phosphotransferase Proteins 0.000 claims description 7
- 102000020233 phosphotransferase Human genes 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 108091026890 Coding region Proteins 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 2
- 101000846284 Homo sapiens Pre-mRNA 3'-end-processing factor FIP1 Proteins 0.000 claims 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 2
- 102100031755 Pre-mRNA 3'-end-processing factor FIP1 Human genes 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 108091005990 tyrosine-phosphorylated proteins Proteins 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 102100033805 Alpha-protein kinase 1 Human genes 0.000 description 2
- 101000779568 Homo sapiens Alpha-protein kinase 1 Proteins 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40233002P | 2002-08-09 | 2002-08-09 | |
| US44049103P | 2003-01-16 | 2003-01-16 | |
| PCT/US2003/024992 WO2004015082A2 (en) | 2002-08-09 | 2003-08-08 | Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010166564A Division JP2010279376A (ja) | 2002-08-09 | 2010-07-23 | 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006515983A JP2006515983A (ja) | 2006-06-15 |
| JP2006515983A5 true JP2006515983A5 (enExample) | 2010-09-16 |
| JP4588447B2 JP4588447B2 (ja) | 2010-12-01 |
Family
ID=31720590
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004527956A Expired - Fee Related JP4588447B2 (ja) | 2002-08-09 | 2003-08-08 | 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法 |
| JP2010166564A Ceased JP2010279376A (ja) | 2002-08-09 | 2010-07-23 | 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010166564A Ceased JP2010279376A (ja) | 2002-08-09 | 2010-07-23 | 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US7195876B2 (enExample) |
| EP (1) | EP1576129A4 (enExample) |
| JP (2) | JP4588447B2 (enExample) |
| AU (1) | AU2003259713A1 (enExample) |
| WO (1) | WO2004015082A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162203A0 (en) * | 2001-12-27 | 2005-11-20 | Theravance Inc | Indolinone derivatives useful as protein inase inhibitors |
| WO2003105773A2 (en) | 2002-06-01 | 2003-12-24 | Oregon Health & Science University | Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets: |
| WO2004015082A2 (en) * | 2002-08-09 | 2004-02-19 | Theravance, Inc. | Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same |
| EP1631291B1 (en) * | 2003-05-27 | 2009-08-12 | Robert P. Hägerkvist | Use of tyrosine kinase inhibitors to treat diabetes |
| US20050171182A1 (en) * | 2003-12-11 | 2005-08-04 | Roger Briesewitz | Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
| MX2008010953A (es) * | 2006-02-28 | 2008-09-08 | Amgen Inc | Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0474744T3 (da) | 1989-05-22 | 1994-11-21 | Zymogenetics Inc | PDGF-alfa-receptor |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| CA2375407A1 (en) | 1999-06-17 | 2000-12-28 | Incyte Genomics, Inc. | Rna metabolism proteins |
| US6573293B2 (en) * | 2000-02-15 | 2003-06-03 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| MXPA03001359A (es) | 2000-08-18 | 2004-12-13 | Millennium Pharm Inc | Derivados de quinazolina como inhibidores de cinasa. |
| IL162203A0 (en) * | 2001-12-27 | 2005-11-20 | Theravance Inc | Indolinone derivatives useful as protein inase inhibitors |
| WO2004015082A2 (en) * | 2002-08-09 | 2004-02-19 | Theravance, Inc. | Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same |
-
2003
- 2003-08-08 WO PCT/US2003/024992 patent/WO2004015082A2/en not_active Ceased
- 2003-08-08 US US10/637,356 patent/US7195876B2/en not_active Expired - Lifetime
- 2003-08-08 EP EP03785118A patent/EP1576129A4/en not_active Withdrawn
- 2003-08-08 AU AU2003259713A patent/AU2003259713A1/en not_active Abandoned
- 2003-08-08 JP JP2004527956A patent/JP4588447B2/ja not_active Expired - Fee Related
-
2007
- 2007-02-15 US US11/706,519 patent/US7585653B2/en not_active Expired - Lifetime
- 2007-12-11 US US12/001,328 patent/US7604944B2/en not_active Expired - Lifetime
-
2009
- 2009-08-26 US US12/548,170 patent/US20100112661A1/en not_active Abandoned
-
2010
- 2010-07-23 JP JP2010166564A patent/JP2010279376A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bennick | Structural and genetic aspects of proline-rich proteins | |
| Cao et al. | TRAF6 is a signal transducer for interleukin-1 | |
| García et al. | Extensive analysis of the human platelet proteome by two‐dimensional gel electrophoresis and mass spectrometry | |
| Božič et al. | Sera from patients with rheumatic diseases recognize different epitope regions on the 52‐kD Ro/SS‐A protein | |
| CA2444680A1 (en) | Binding molecules for fc-region polypeptides | |
| JP2000312590A5 (enExample) | ||
| CA2290886A1 (en) | Nucleic acid binding proteins | |
| AU2002254683A1 (en) | Binding molecules for Fc-region polypeptides | |
| Li et al. | ATAD3, a vital membrane bound mitochondrial ATPase involved in tumor progression | |
| WO2001027158A2 (en) | Olfactory receptor sequences | |
| ATE369440T1 (de) | Rationale auswahl von mutmasslichen peptiden aus identifizierten nukleotid- beziehungsweise peptidsequenzen | |
| KR950704483A (ko) | 사이클린 복합체 재배열 및 그것과 관련된 용도(cyclin complex rearrangement and uses related thereto) | |
| TW201741670A (zh) | 測量天然殺手細胞活性之方法和診斷套組 | |
| WO2002059604A2 (en) | Diagnosis and treatment of multiple sclerosis | |
| WO2002032953A3 (en) | Pregnancy-associated plasma protein-a2 (papp-a2) | |
| JPH1099087A5 (enExample) | ||
| CN110832326A (zh) | 变态反应的抗原及其表位 | |
| JP2006515983A5 (enExample) | ||
| Andersson et al. | Extended cleavage specificity of mMCP-1, the major mucosal mast cell protease in mouse—High specificity indicates high substrate selectivity | |
| CN1700930A (zh) | 炎症和细胞凋亡相关的方法与试剂 | |
| Cui et al. | Primary structure and functional characterization of rat C5a: an anaphylatoxin with unusually high potency | |
| WO2002046767A2 (en) | Diagnosis and treatment of alzheimer's disease | |
| CN108948153B (zh) | 一种瓜氨酸修饰肽抗原组合及其应用 | |
| Elphick et al. | Molecular characterisation of SALMFamide neuropeptides in sea urchins | |
| JP2005507246A5 (enExample) |